Author:
Riley Fleur,Harris Magdalena,Poulter Hannah Louise,Moore Helen J.,Ahmed Daniel,Towl Graham,Walker Tammi
Abstract
Abstract
Background
Heroin-Assisted Treatment (HAT) is well evidenced internationally to improve health and social outcomes for people dependent on opioids who have not been helped by traditional treatment options. Despite this evidence base, England has been slow to implement HAT. The first service outside of a trial setting opened in 2019, providing twice-daily supervised injections of medical-grade heroin (diamorphine) to a select sample of high-risk heroin users in Middlesbrough. This paper explores their experiences, including the negotiation of the strict regularly controls required of a novel intervention in the UK context.
Methods
We conducted in-depth interviews with service providers and users of the Middlesbrough HAT service between September and November 2021. Data from each group were thematically analysed and reported separately. This paper details the experiences of the twelve heroin dependent men and women accessing HAT.
Results
Participants’ accounts of HAT treatment evidenced a tension between the regulatory constraints and uncertainty of treatment provision, and the positive outcomes experienced through supportive service provision and an injectable treatment option. Limited confidence was held in treatment efficacy, longevity of funding, and personal capacity for treatment success. This was counteracted by a strong motivation to cease engagement with the illicit drug market. While attendance requirements placed restrictions on daily activities, participants also experienced benefits from strong, supportive bonds built with the service providers through their continued engagement.
Conclusions
The Middlesbrough HAT programme provided benefits to a high-risk population of opioid dependent people who were unable or disinclined to participate in conventional opioid substitution treatments. The findings in this paper highlight the potential for service modifications to further enhance engagement. The closure of this programme in 2022 prohibits this opportunity for the Middlesbrough community, but holds potential to inform advocacy and innovation for future HAT interventions in England.
Funder
National Institute for Health and Care Research
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Public Health, Environmental and Occupational Health,Medicine (miscellaneous)
Reference75 articles.
1. Public Health England. United Kingdom drug situation 2019: Focal Point annual report. 2021 [cited 2022 Nov 24]. Available from: https://www.gov.uk/government/publications/united-kingdom-drug-situation-focal-point-annual-report/united-kingdom-drug-situation-focal-point-annual-report-2019
2. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Drug-related deaths and mortality in Europe. 2019 [cited 2022 Nov 24]. Available from: https://www.emcdda.europa.eu/system/files/publications/11485/20193286_TD0319444ENN_PDF.pdf
3. Office for National Statistics (ONS). Deaths related to drug poisoning in England and Wales: 2020 registrations. 2020 2021 [cited 2022 Nov 24]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2020
4. Poulter HL, Moore H, Crow R, Ahmed D, Walker T. Diamorphine assisted treatment in Middlesbrough: a UK drug treatment case study. J Subst Use. 2022;14:1–7.
5. Nahar LK, Murphy KG, Paterson S. Misuse and mortality related to gabapentin and pregabalin are being under-estimated: a two-year post-mortem population study. J Anal Toxicol. 2019;43(7):564–70.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献